Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 171-180 of 682 for cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study Of BH-30643 In Subjects With Locally Advanced Or Metastatic NSCLC Harboring EGFR And/or HER2 Mutations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Study Of Datopotamab Deruxtecan Plus Carboplatin Or Cisplatin Versus Gemcitabine Plus Carboplatin Or Cisplatin In Participants With Locally Advanced Or Metastatic Urothelial Carcinoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. CBT Based Pain Management Program For The Treatment Of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) In Breast Cancer Survivors

    Jacksonville, FL

  4. Sacituzumab Tirumotecan (MK-2870) In Combination With Pembrolizumab Versus Pembrolizumab Alone In Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    Eau Claire, WI, Jacksonville, FL, Rochester, MN

  6. Study Of The Theranostic Pair RYZ811 (Diagnostic) And RYZ801 (Therapeutic) To Identify And Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study Using A New Drug, Nivolumab, In Combination With Chemotherapy Drugs To Treat A Type Of Cancer Called Nasopharyngeal Carcinoma (NPC)

    Rochester, MN

  8. Study Of Carboplatin And Mirvetuximab Soravtansine In First-Line Treatment Of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

    Rochester, MN

  9. Adding The Immunotherapy Drug Cemiplimab To Usual Treatment For People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy And Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    Rochester, MN

  10. Decitabine In Combination With Standard Of Care Therapy For The Treatment Of Surgically Resectable HPV-Negative Head And Neck Cancer

    Jacksonville, FL

.

Mayo Clinic Footer